FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Education to Targeted Risk Assessment
The legacy context of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad framework, discussions of pharmaceutical interventions have historically emphasized their intended benefits while acknowledging potential adverse effects in a balanced manner. This heritage of health communication provides a necessary backdrop for examining specific medication-related concerns that arise in both clinical and occupational settings. As we pivot from this general health perspective toward more focused exposure considerations, the transition naturally leads to examining how certain medications may present distinct risks in particular contexts. The shift from broad health education to targeted risk assessment requires careful attention to the pathways through which pharmaceutical agents interact with biological systems. In occupational environments, where individuals may face repeated or prolonged exposure to various substances, the evaluation of medication-related risks takes on additional dimensions. This includes considering how workplace factors might influence susceptibility or modify the relationship between drug exposure and adverse outcomes. The following discussion narrows this focus to examine the specific question of whether bisphosphonate therapy, commonly prescribed for bone health, may be associated with osteonecrosis of the jaw, particularly when considered through the lens of exposure duration and individual risk factors that are relevant in both clinical and occupational health contexts.
Fosamax and Osteonecrosis of the Jaw: The Evidence
Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. Clinical presentation and diagnosis of ONJ typically involve exposed bone in the maxillofacial region that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with the jawbone showing characteristic necrotic changes. Multiscale characterization of jawbone tissue provides comprehensive information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).
Mechanisms and Risk Factors
The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. In the jaw, which has high bone remodeling rates due to constant mechanical stress and dental infections, this suppression can lead to microdamage accumulation and impaired healing. Bisphosphonates also have anti-angiogenic properties, reducing blood supply to the jawbone, and may alter immune responses, increasing susceptibility to infection. These factors, combined with local trauma from dental procedures, can precipitate ONJ. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Fosamax and how does it work?
Fosamax (alendronate) is a bisphosphonate medication approved for treating and preventing osteoporosis, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Does Fosamax cause osteonecrosis of the jaw?
Yes, Fosamax is associated with an increased risk of osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. The risk is higher in patients with additional risk factors such as invasive dental procedures, cancer, or prolonged bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What are the risk factors for developing ONJ while taking Fosamax?
Risk factors include invasive dental procedures (e.g., tooth extraction, dental implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures. The risk increases with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.